Treatment strategy based on the clinical efficacy and safety of bolus infusion of ulinastatin, a human urinary trypsin inhibitor to refractory interstitial pneumonia in patients with systemic connective tissue diseases.
| Project/Area Number |
23791127
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
膠原病・アレルギー・感染症内科学
|
|---|
| Research Institution | University of Occupational and Environmental Health, Japan |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2011 – 2012
|
| Project Status |
Completed (Fiscal Year 2012)
|
| Budget Amount *help |
¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2012: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2011: ¥2,340,000 (Direct Cost: ¥1,800,000、Indirect Cost: ¥540,000)
|
|---|
| Keywords | 膠原病学 / 薬剤抵抗性 / 活動性間質性肺炎 / 膠原病 / ウリナスタチン / 難治性 / 臨床研究 / 安全性 / 間質性肺炎 / 治療抵抗性 |
|---|
| Research Abstract |
Ulinastatin, a human urinary trypsin inhibitor, has anti-inflammatory and organ-protective effects without cytotoxicity. We investigated efficacy and safety of bolus infusion of ulinastatin (UT pulse) in patients with systemic connective tissue diseases -associated active interstitial pneumonia refractory to conventional treatments. Informed consent was obtained from the all patients. 20 patients received UT inhibitor infusion into internal jugular vein, 3 times in a single day. CT score in 14 of 20 patients was inhibited the exacerbation or improved. KL-6 in 18 of 20 patients showed decrease.
We thereby propose that UT pulse is efficacious and safe for refractory SCTD associated-IP in the patients with various complications.
|
Report
(3 results)
Research Products
(14 results)
